| Followers | 3162 |
| Posts | 209548 |
| Boards Moderated | 1 |
| Alias Born | 02/04/2004 |
Wednesday, May 08, 2019 11:34:51 AM
Not even remotely true, as their Q1 soft launch endeavors has resulted in a multitude of Vtex CLOUD bed-in-a-box and associated bedding products being sold on several mainstream retailers like Amazon, Bed Bath and Beyond, Sears, Walmart, Wayfair etc, so clearly their Q1 revenue growth is going to be significant...and that's on top of all the additional mainstream mattress lines that incorporate the Vytex proprietary competitive advantage latex into their mattress lines also being sold in a multitude of mainstream retailers.
So no-one can suggest/state with any remote degree of confidence that VYST's Vytex subsidiary division alone hasn't begun to rapidly increase their revenues throughout Q1, and now into Q2. And additionally, we just got a VYST tweet the other day that reflects the VYST RxAir subsidiary division just went back into Q2 production on 100 units in only 1 week that equates to approx. $100K in value, which reflects additional revenue has begun flowing from the new RxAir launch and commercialization endeavors that include the FEC enhancements to the new Rx3000 units, making the RxAir division more competitive and a lot better equipped to capitalize on the rising demand the measles outbreaks have created.
And VYST also secured approx. $200K in convertible note bridge loan financing from a group of their VYST insiders, along with an initial $400K teaser tranche of friendly private placement financing, while they simultaneously eliminated ALL 3rd party convertible noteholders from their ever-evolving/emerging growth driving equation in Q1.
So next weeks Q1 earnings results are going to soon be reflecting just how much revenue growth kicked in during all their fresh launch and commercialization endeavors that has continued into this current 2nd quarter, with a multitude of other proprietary competitive advantage products(as extensively outlined in their 10-K) all preparing to get launched as well, after several quarters of extensive R&D talks/testing has already occurred, many of which with big names.
And VYST's subsidiary companies and extensive roster of astute and affluent insiders haven't spent millions of dollars on years of extensive R&D endeavors for nothing, which they will soon begin proving to the world by way of all the new contracts logic strongly suggests they're now on the verge of securing all summer long...and no-one knows what share repurchase program monies may still be deployed, let alone what other creative insider share retirements or share exchange creative solutions may come into play ahead of their eventual Nasdaq up listing application objective.
The bottom line from here is that CEO Rotman is preparing to unleash a dramatic and explosive increase in value with all 3rd party convertible noteholders eliminated from VYST's ongoing growth driving equation...and when he does insert the final key foundational leverageable Rotmans building block it's going to be a game changer of beyond epic proportions for all the additional fresh contracts and additional accretive acquisition catalysts coming right behind it:)
So no-one can suggest/state with any remote degree of confidence that VYST's Vytex subsidiary division alone hasn't begun to rapidly increase their revenues throughout Q1, and now into Q2. And additionally, we just got a VYST tweet the other day that reflects the VYST RxAir subsidiary division just went back into Q2 production on 100 units in only 1 week that equates to approx. $100K in value, which reflects additional revenue has begun flowing from the new RxAir launch and commercialization endeavors that include the FEC enhancements to the new Rx3000 units, making the RxAir division more competitive and a lot better equipped to capitalize on the rising demand the measles outbreaks have created.
And VYST also secured approx. $200K in convertible note bridge loan financing from a group of their VYST insiders, along with an initial $400K teaser tranche of friendly private placement financing, while they simultaneously eliminated ALL 3rd party convertible noteholders from their ever-evolving/emerging growth driving equation in Q1.
So next weeks Q1 earnings results are going to soon be reflecting just how much revenue growth kicked in during all their fresh launch and commercialization endeavors that has continued into this current 2nd quarter, with a multitude of other proprietary competitive advantage products(as extensively outlined in their 10-K) all preparing to get launched as well, after several quarters of extensive R&D talks/testing has already occurred, many of which with big names.
And VYST's subsidiary companies and extensive roster of astute and affluent insiders haven't spent millions of dollars on years of extensive R&D endeavors for nothing, which they will soon begin proving to the world by way of all the new contracts logic strongly suggests they're now on the verge of securing all summer long...and no-one knows what share repurchase program monies may still be deployed, let alone what other creative insider share retirements or share exchange creative solutions may come into play ahead of their eventual Nasdaq up listing application objective.
The bottom line from here is that CEO Rotman is preparing to unleash a dramatic and explosive increase in value with all 3rd party convertible noteholders eliminated from VYST's ongoing growth driving equation...and when he does insert the final key foundational leverageable Rotmans building block it's going to be a game changer of beyond epic proportions for all the additional fresh contracts and additional accretive acquisition catalysts coming right behind it:)
Recent VYST News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/30/2026 03:33:28 PM
- Vystar Announces 2-Week-Long Memorabilia Sweepstakes on X Platform • GlobeNewswire Inc. • 02/18/2026 02:30:00 PM
- Vystar Enters Final Testing of Breakthrough Dialysis Water Filtration Technology • GlobeNewswire Inc. • 01/29/2026 03:40:00 PM
- Vystar to Acquire Stake in GoPaid and Partner with Capital R3alm to Launch R3alm Oracle and Collectibles Platform • GlobeNewswire Inc. • 01/27/2026 03:57:10 PM
- Vystar Corp. Submits Binding Letter of Intent to Acquire Stake in GoPaid.com LLC and Form Strategic Partnership with Capital R3alm to Launch R3alm Oracle and R3alm Collectibles • GlobeNewswire Inc. • 01/08/2026 04:40:38 PM
- Vystar® Reports, Following its First of its Kind Court Victory against EMA Financial, Inc. of $497,439.58 in Legal Fees and Costs Awarded. • GlobeNewswire Inc. • 12/22/2025 08:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 05:59:16 PM
- Incubator Stock Review Initiates Coverage on Vystar • GlobeNewswire Inc. • 10/24/2025 02:05:00 PM
- Vystar’s Vytex® Cloud Bed-in-a-Box Available for Sale • GlobeNewswire Inc. • 10/17/2025 12:30:00 PM
- Vystar® to restart sales of Vytex® Cloud Bed-in-a-Box • GlobeNewswire Inc. • 09/12/2025 01:20:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2025 04:16:02 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/14/2025 10:22:25 AM

